Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripertamab and Eltrombopag for Primary Immune Thrombocytopenia (RPE-ITP)
NCT06790888Not yet recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, open-label trial of ripertamab in primary immune thrombocytopenia (ITP) (2 arms). Primary endpoint: Sustained Response Rate at 12 Weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ripertamab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06790888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790888.